Cargando…

Ocriplasmin for symptomatic vitreomacular adhesion: an evidence-based review of its potential

Vitreomacular traction is a multicategory entity that may cause substantial visual loss due to the formation of a macular hole or traction-induced tissue distortion. The advent of optical coherent tomography (OCT) has demonstrated the anatomic features of persistent vitreomacular attachment (VMA) mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Su Jeong, Smiddy, William E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3968080/ https://www.ncbi.nlm.nih.gov/pubmed/24711777 http://dx.doi.org/10.2147/CE.S39363

Ejemplares similares

Profile of ocriplasmin and its potential in the treatment of vitreomacular adhesion
por: Stefanini, Francisco R, et al.
Publicado: (2014)

Ocriplasmin for Treatment of Vitreomacular Traction: An Update
por: Khan, Mohammed Ali, et al.
Publicado: (2016)

PATIENT-REPORTED VISUAL FUNCTION FROM THE OCRIPLASMIN FOR TREATMENT FOR SYMPTOMATIC VITREOMACULAR ADHESION, INCLUDING MACULAR HOLE (OASIS) STUDY
por: Mein, Calvin, et al.
Publicado: (2020)

Incomplete Vitreomacular Traction Release Using Intravitreal Ocriplasmin
por: Chin, Eric K., et al.
Publicado: (2014)

OCRIPLASMIN FOR VITREOMACULAR TRACTION IN CLINICAL PRACTICE: The INJECT Study
por: Steel, David H. W., et al.
Publicado: (2020)

Efficacy and Safety of Ocriplasmin Use for Vitreomacular Adhesion and Its Predictive Factors: A Systematic Review and Meta-Analysis
por: Chen, Xi, et al.
Publicado: (2022)

Cost-effectiveness of ocriplasmin for the treatment of vitreomacular traction and macular hole
por: Bennison, Craig, et al.
Publicado: (2016)

Prognostic Factors Associated with Ocriplasmin Efficacy for the Treatment of Symptomatic Vitreomacular Adhesion and Full-thickness Macular Hole: Analysis from Four Studies
por: Joondeph, Brian C., et al.
Publicado: (2021)

Visual function response to ocriplasmin for the treatment of vitreomacular traction and macular hole
por: Jackson, Timothy L., et al.
Publicado: (2017)

Transient visual loss and delayed resolution of vitreomacular traction after intravitreal ocriplasmin
por: DaCosta, Joanna, et al.
Publicado: (2014)

Early vitreomacular separation with delayed macular hole closure after ocriplasmin treatment
por: Liang, I-Chia, et al.
Publicado: (2016)

Functional improvement assessed by multifocal electroretinogram after Ocriplasmin treatment for vitreomacular traction
por: Rossi, Settimio, et al.
Publicado: (2016)

Vitreomacular traction quantitative cutoffs for the assessment of resolution after ocriplasmin intravitreal treatment
por: Arrigo, Alessandro, et al.
Publicado: (2020)

Recurrent Vitreomacular Traction in a Patient Treated with Ocriplasmin: A Case Report
por: Katsanos, Andreas, et al.
Publicado: (2020)

Effect of Funding Source on “Spin” in Studies of Ocriplasmin Therapy for Vitreomacular Traction and Macular Hole
por: Hubschman, Sasha, et al.
Publicado: (2020)

Patient-reported outcomes of ocriplasmin for the treatment of vitreomacular traction: a systematic review and synthesis of the literature
por: Lescrauwaet, Benedicte, et al.
Publicado: (2019)

Comparison of Guided and Unguided Ocriplasmin Injection for the Treatment of Vitreomacular Traction: A Preliminary Study
por: Mastropasqua, Rodolfo, et al.
Publicado: (2016)

Visual functional changes after ocriplasmin injection for vitreomacular traction: A microperimetric analysis
por: Furino, Claudio, et al.
Publicado: (2020)

Intravitreal ocriplasmin for the treatment of vitreomacular traction and macular hole- A study of efficacy and safety based on NICE guidance
por: Muqit, Mahiul M. K., et al.
Publicado: (2018)

Ocriplasmin in the Treatment of Vitreomacular Traction in a Patient with Central Retinal Vein Occlusion: A Case Report
por: Rosati, Alessandra, et al.
Publicado: (2018)

Reduced perfusion density of superficial retinal capillary plexus after intravitreal ocriplasmin injection for idiopathic vitreomacular traction
por: Iuliano, Lorenzo, et al.
Publicado: (2019)

Calculating the individual probability of successful ocriplasmin treatment in eyes with vitreomacular traction–Validation and refinement of a multivariable prediction model
por: Paul, Christoph, et al.
Publicado: (2022)

Treatment of Symptomatic Vitreomacular Adhesion with Expansile Sulfur Hexafluoride (SF6) Gas
por: Buzzacco, Dominic M, et al.
Publicado: (2017)

ASSESSMENT OF ANATOMICAL AND FUNCTIONAL OUTCOMES WITH OCRIPLASMIN TREATMENT IN PATIENTS WITH VITREOMACULAR TRACTION WITH OR WITHOUT MACULAR HOLES: Results of OVIID-1 Trial
por: Tadayoni, Ramin, et al.
Publicado: (2019)

Predicting the individual probability of macular hole closure following intravitreal ocriplasmin injections for vitreomacular traction release using baseline characteristics
por: Bertelmann, Thomas, et al.
Publicado: (2021)

Pneumatic Vitreolysis for Management of Symptomatic Focal Vitreomacular Traction
por: Chan, Clement K., et al.
Publicado: (2017)

Ocriplasmin: who is the best candidate?
por: Prospero Ponce, Claudia M, et al.
Publicado: (2016)

Ocriplasmin for Vitreoretinal Diseases
por: Tsui, Irena, et al.
Publicado: (2012)

Emerging nonsurgical methods for the treatment of vitreomacular adhesion: a review
por: Schneider, Eric W, et al.
Publicado: (2011)

Effects of Vitreomacular Adhesion on Age-Related Macular Degeneration
por: Kang, Eui Chun, et al.
Publicado: (2015)

OCT proves that vitreomacular adhesion is significantly more likely to develop vision-threatening retinal complications than vitreomacular separation
por: Liao, Ding-Ying, et al.
Publicado: (2020)

Effect of pneumatic vitreolysis in management of patients with symptomatic focal vitreomacular traction
por: Fouad, Ahmed N., et al.
Publicado: (2022)

Clinical Features of Vitreomacular Traction Syndrome with Peripheral Vitreoretinal Adhesion
por: Fukumoto, Masanori, et al.
Publicado: (2020)

Post hoc analysis of ellipsoid zone changes beyond the central subfield in symptomatic vitreomacular adhesion patients from the OASIS trial
por: Velaga, Swetha Bindu, et al.
Publicado: (2021)

Retinal breaks due to intravitreal ocriplasmin
por: Silva, Ruwan A, et al.
Publicado: (2014)

The Vitreomacular Interface in Diabetic Retinopathy
por: Agarwal, Daniel, et al.
Publicado: (2015)

Rhegmatogenous retinal detachment following intravitreal ocriplasmin
por: Madi, Haifa A., et al.
Publicado: (2016)

Italian real-life experience on the use of ocriplasmin
por: Barca, Francesco, et al.
Publicado: (2018)

Vitreomacular Traction Syndrome
por: Bottós, Juliana, et al.
Publicado: (2012)

Vitreomacular traction syndrome
por: Martins, Thiago Gonçalves dos Santos, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ub35e9jro164mb36ek5jl03dje